Press release
Illumina Board Chair issues letter to shareholders and urges shareholders to vote the WHITE proxy card FOR all nine of Illumina's nominees
Board Chair John Thompson issues letter to Illumina shareholders ahead of the company's Annual Meeting on May 25, 2023, at 10:00 am Pacific Time (1:00 pm
About this update from Illumina, Inc.
[{"type":"text","content":"Board Chair John Thompson issues letter to Illumina shareholders ahead of the company's Annual Meeting on May 25, 2023, at 10:00 am Pacific Time (1:00 pm Eastern Time)Illumina requests shareholders to vote the WHITE proxy card today FOR all nine of Illumina's director nomineesFor more information, visit www.IlluminaForward.comSAN DIEGO, May 18, 2023 /PRNewswire/ -- Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today issued a shareholder letter from Board Chair John Thompson.\nIn his letter, Mr. Thompson reiterated the specific steps the company is taking to deliver results consistent with the high standards of performance and value creation expected by shareholders.\nMr. Thompson and the entire Board of Directors at Illumina request that shareholders protect their investment by voting the WHITE proxy card today FOR all nine of the company's deeply experienced director nominees. The Annual Meeting will be held on May 25, 2023, at 10:00 am Pacific Time (1:00 pm Eastern Time). Shareholders of record as of close of business on April 3, 2023, are entitled to vote at the meeting, no matter how many or how few shares they own.\nThe full text of the letter follows:\nVOTE USING THE WHITE PROXY CARD TODAY IN SUPPORT OF ILLUMINA'S NINE HIGHLY QUALIFIED DIRECTORS\nMay 18, 2023\nFellow Shareholders,\nAs Independent Chair of the Board of Illumina, I am writing today to share some reflections and my perspectives on the real \"state of Illumina\" as we quickly approach our contested Annual Meeting on May 25.\nMy fellow directors and I have met with each of our top shareholders to describe our plan for the company and, most importantly, take and act on shareholder feedback. While support for the company is widespread, there is no doubt that a number of shareholders have had well-reasoned and pointed feedback for us as a Board, for Francis, and for the management team. We have heard these views and we understand the perspectives. While Illumina continues to strive to improve what is possible in healthcare, our financial results and shareholder returns have not met shareholder expectations, nor our own expectations for ourselves.\nI will describe how we plan to address these issues, and how the Board will continue to drive accountability for each:\nOn operating performance, we have challenged management t...